Indian Pharma API + Bulk Drug Plant MEP — Schedule M 2023 + USFDA 21 CFR 211 + ICH Q7 + WHO TRS 1019

By /
MEP Consultant · Pharma / API · 12 May 2026

Indian Pharma API + Bulk Drug Plant MEP — Schedule M 2023 + USFDA 21 CFR 211 + ICH Q7 + WHO TRS 1019

Published: 07 May 2026Updated: 12 May 2026Original figures: 9

A 500 t/yr Indian pharma API + bulk drug plant demands ₹895 Cr MEP capex with synthesis reactor halls + crystallisation + drying + QC labs + ICH Q1A stability chambers + solvent vapour recovery (> 95 %) + ETP-ZLD with MEE crystalliser. Schedule M 2023 + USFDA 21 CFR 211 + WHO TRS 1019 + ICH Q7 + EU Annex 18 + ISPE govern. Three failures: solvent recovery < 95 % emitting 800-1500 mg/Nm³ vs CPCB 5 limit, stability chamber temperature mapping skipped failing USFDA, ETP without MEE crystalliser causing state PCB closures 2022-2024.

Indian pharma API plant + bulk drug manufacturing framework

India is the worlds 3rd-largest pharma API producer (Dr Reddys + Sun Pharma + Cipla + Aurobindo + Divis + Hetero + Lupin + Torrent + Glenmark + Strides). API plants make bulk active ingredients via fermentation / chemical synthesis. Standards stack — Schedule M revised Dec 2023 + USFDA cGMP 21 CFR 211 + WHO TRS 1019 Annex 3 (APIs) + ICH Q7 (API GMP) + EU EMA Annex 18 + ISPE Baseline Vol 1 (APIs) + ISO 14644 + 14001 + USP 1116 + India Drugs + Cosmetics Rules.

500 t/yr API plant MEP scope — multi-product bulk drugs

Zone Activity Grade Capex (₹ Cr)
Raw material warehouse controlled climate 22 ± 2°C / 60 % RH 25
Solvent storage tank-farm flammable + toxic Class 1 Div 1 35
Synthesis reactor hall (kilo-lab) 100-1500 L glass-lined D-grade 85
Synthesis reactor hall (production) 5000-20000 L SS-316 C-grade 185
Crystallisation + filtration centrifuge + filter-dryer C-grade 62
Drying + milling vacuum dryer + jet mill C-grade 45
Packaging + finished product — D-grade 35
QC + microbiology lab — ISO 17025 + GLP 62
Stability chambers (ICH Q1A) 25°C/60% + 40°C/75% + 30°C/65% — 22
HVAC + dehumidification — — 85
Boiler + steam plant 15 t/hr IBR 42
Process cooling water — CTI 25
Solvent vapour recovery (VOC < 5 mg/Nm³) activated carbon + condenser CPCB 62
ETP + ZLD (toxic + AOX) RO + MEE + crystalliser CPCB Pharma 125
Total API plant MEP — — 895

Indian pharma API plant capex (₹ Cr) — by annual production50 t/yr boutique185Cr150 t/yr mid420Cr500 t/yr (typical)895Cr1500 t/yr large1850Cr3000 t/yr mega-plant3450Cr5000 t/yr (Sun-Aurobindo class)5800CrSolvent vapour recovery + ETP capex (₹ Cr) by API toxic loadLow-toxic (paracetamol)22CrMid-toxic (cardio)45CrHi-toxic (oncology)85CrHi-AOX (chlorinated)125CrAPI + ETO (sterilisation)165CrAPI + cytotoxic220Cr

Three Indian pharma API plant MEP failures

  1. Solvent vapour recovery < 95 % — USFDA + CPCB + EU EMA require > 95 % solvent recovery. Indian legacy plants emit 800-1500 mg/Nm³ vs CPCB 5 mg/Nm³ limit. Specify activated carbon + condenser + cryogenic recovery for chlorinated.
  2. Stability chamber temperature mapping skipped — ICH Q1A + WHO TRS 1019 require chamber mapping with 27 sensor grid + 24-hr trend + door-open recovery. USFDA inspection failure most common. Specify mapping at IQ + annual re-validation.
  3. ETP ZLD without MEE crystalliser — pharma effluent contains chlorinated + AOX + heavy-metal residue. Standard RO inadequate; need MEE + crystalliser to ZLD per Maharashtra + Telangana + Andhra state pollution control. Many APIs face state PCB closure 2022-2024 for non-compliance.
// References + Standards
  1. Schedule M Drugs + Cosmetics Rules 1945 revised 28 Dec 2023 (India).
  2. USFDA 21 CFR Part 211 cGMP + Guidance for Industry on APIs 2024.
  3. WHO Technical Report Series No. 1019 Annex 3 — Good Manufacturing Practices for APIs.
  4. ICH Q7:2000 + Q1A R2 — GMP for APIs + Stability Testing.
  5. EU EMA Annex 18 — APIs.
  6. ISPE Baseline Guide Vol 1 — Active Pharmaceutical Ingredients 2018.
  7. USP 1116 — Microbiological Control + Monitoring of Aseptic Processing Environments.
  8. CPCB Pharma Industry Effluent Standards 2022 (ZLD for selected states).
By MEPVAULT Editorial Team — A team of practising MEP consultants based in India. ISHRAE-affiliated; FSAI-aligned.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top